Entering text into the input field will update the search result below

Biocept up 28% premarket on launch of lung cancer test

May 20, 2019 8:58 AM ETBiocept, Inc. (BIOCQ) StockBy: Douglas W. House, SA News Editor1 Comment
  • Nano cap Biocept (NASDAQ:BIOC) is up 28% premarket on robust volume in reaction to the commercial launch of its Target Selector NGS Lung panel, a multi-gene liquid biopsy test for lung cancer.

Recommended For You

About BIOCQ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BIOCQ--
Biocept, Inc.